Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ENZON PHARMACEUTICALS INCv329484_ex99-1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 29, 2012

ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

 

Delaware 0-12957 22-2372868
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

 

 

 

20 Kingsbridge Road, Piscataway, New Jersey
(Address of principal executive offices)
08854
(Zip Code)

(732) 980-4500
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 8.01 Other Events.

 

On November 29, 2012, Enzon Pharmaceuticals, Inc. issued a press release announcing that its board of directors authorized a special dividend of $2.00 per common share, payable on December 21, 2012 to shareholders of record as of December 10, 2012.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 



     
Exhibit
No.
  Description

 

 

 

99.1   Press Release of Enzon Pharmaceuticals, Inc. dated November 29, 2012
 
 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  ENZON PHARMACEUTICALS, INC.
                  (Registrant)
   
Date:  November 29, 2012 By:  /s/ Andrew Rackear
  Name:  Andrew Rackear
  Title:  Vice President and General Counsel

 

 
 

EXHIBIT INDEX

 



     
Exhibit
No.
  Description

 

 

 

99.1   Press Release of Enzon Pharmaceuticals, Inc. dated November 29, 2012